Traws Pharma Inc. (NASDAQ: TRAW) on Wednesday shared interim data from an ongoing randomized, open-label Phase 2 with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor.

The AI race between OpenAI and Google is heating up with the release of GPT-5.2. How does it compare to Gemini 3? Credit: Avishek Das/SOPA Images/LightRocket via Getty Images OpenAI's latest AI model ...

New York rallied from an 11-point second-half deficit to beat San Antonio 124-113 in the NBA Cup championship game. The Knicks outscored the Spurs 35-19 in the fourth quarter and held a 67-56 ...

First Federal Bank stands out for its exceptionally low interest rates and its emphasis on government loans. Most likely to appeal to borrowers shopping for low rates and fees. Strong experience in ...

Apple's latest phone has a lot in common with the previous model, but there are notable improvements to the camera, display and battery. Is it worth the upgrade? Abrar's interests include phones, ...

India vs Argentina Highlights, FIH Hockey Men's Junior World Cup 2025 Third-Place Match: India produced a breathtaking late surge to beat Argentina 4-2 and secure bronze at the FIH Junior World Cup ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

The Federal Reserve wrapped up 2025 with three rate cuts that brought the federal funds rate down to a range between 3.5% and 3.75%. That shift is rippling through the banking system, but not at the ...